Discounted Cash Flow
Arbutus Biopharma Corp.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $1.5m | $-278.5m | $-44.9m | -18680.5% | $-7.24 |
| 2017 | $10.7m (617.6%) | $-61.2m (78.0%) | $-40.5m (9.7%) | -572.0% (96.9%) | $-1.56 (78.5%) |
| 2018 | $5.9m (-44.4%) | $-41.4m (32.4%) | $-50.0m (-23.4%) | -695.9% (-21.7%) | $-1.21 (22.4%) |
| 2019 | $6.0m (1.1%) | $-111.5m (-169.4%) | $-51.9m (-3.8%) | -1854.1% (-166.4%) | — |
| 2020 | $6.9m (15.0%) | $-46.2m (58.5%) | $-37.5m (27.8%) | -668.4% (63.9%) | — |
| 2021 | $11.0m (58.9%) | $-55.3m (-19.6%) | $-49.5m (-32.3%) | -503.1% (24.7%) | $-0.83 |
| 2022 | $39.0m (255.1%) | $-50.4m (8.9%) | $-26.0m (47.5%) | -129.1% (74.3%) | $-0.46 (44.6%) |
| 2023 | $18.1m (-53.5%) | $-52.8m (-4.9%) | $-63.0m (-142.4%) | -291.1% (-125.6%) | $-0.44 (4.3%) |
| 2024 | $6.2m (-66.0%) | $-50.7m (4.0%) | $-47.1m (25.2%) | -821.5% (-182.2%) | $-0.38 (13.6%) |
| 2025 | $14.1m (128.2%) | $-24.3m (52.1%) | $-28.7m (39.1%) | -172.5% (79.0%) | $-0.17 (55.3%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
SEC filings report in CAD. Values above are converted to USD for comparison with the US-listed share price.
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.